Lipid Nanoparticle (LNP) News Brief Summary (May 13 – May 26, 2025)
- aprilt97
- 7 days ago
- 2 min read
News Summary
Innorna: Presented new data on mRNA-LNP therapies for PFIC2 and Wilson’s Disease at ASGCT 2025.
University of Nottingham, MIT, Sail Biomedicines: Developed cryogenic mass spectrometry to analyze LNP surface structures.
Sail Biomedicines: Announced preclinical data on in vivo eRNA CAR-T candidate SAIL-0804 for autoimmune diseases.
Arcturus Therapeutics: SWOT analysis highlighted LNP platform advancements and pipeline progress.
ResearchAndMarkets.com: Reported mRNA platform market growth driven by LNP delivery innovations.
Detailed News Summaries
Innorna: Advances in mRNA-LNP Therapies at ASGCT 2025
Release Date: May 13, 2025
Related Institutions: Innorna (Boston, Hong Kong, Shenzhen, China).
Innorna presented two posters at the ASGCT Annual Meeting showcasing mRNA-LNP formulations targeting Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2) and Wilson’s Disease. Their LNPs demonstrated high liver-targeting efficiency and safety in preclinical models, supporting clinical translation for rare liver diseases.
University of Nottingham, MIT, Sail Biomedicines: Cryo-OrbiSIMS for LNP Analysis
Release Date: May 22, 2025
Authors: Professor Morgan Alexander (Nottingham), Dr. Robert Langer (MIT), Kerry Benenato (Sail Biomedicines).
Related Institutions: University of Nottingham (Nottingham, UK); MIT (Cambridge, MA, USA); Sail Biomedicines (Cambridge, MA, USA); National Physical Laboratory (Teddington, UK).
A collaborative study published in Nature introduced Cryogenic Orbitrap Secondary Ion Mass Spectrometry (Cryo-OrbiSIMS) to map molecular layers in hydrated LNPs. This method revealed PEG-lipid orientation and RNA distribution, enabling precise engineering of LNPs for improved drug delivery.
Sail Biomedicines: Preclinical Data on SAIL-0804 for Autoimmune Diseases
Release Date: May 13, 2025
Related Institutions: Sail Biomedicines (Cambridge, MA, USA).
Sail Biomedicines presented data on SAIL-0804, an in vivo CAR-T therapy delivered via targeted LNPs. The candidate induced rapid B-cell depletion in preclinical models, supporting its advancement into IND-enabling studies for autoimmune diseases.
Arcturus Therapeutics: SWOT Analysis Highlights LNP Platform
Release Date: May 24, 2025
Link: Arcturus SWOT Analysis
Related Institutions: Arcturus Therapeutics (San Diego, CA, USA).
A financial analysis highlighted Arcturus’ LUNAR® LNP platform, which underpins its self-amplifying mRNA pipeline. Key programs include ARCT-032 (cystic fibrosis) and ARCT-2304 (H5N1 vaccine), with Phase 2 data expected in 2025.
mRNA Platform Market Report: LNP Delivery Innovations
Release Date: May 23, 2025
Link: mRNA Market Report
Related Institutions: ResearchAndMarkets.com (Dublin, Ireland).
The report projected the mRNA market to reach $8.93B by 2030, driven by LNP advancements improving stability and cellular uptake. Collaborations like BioNTech-CEPI for mpox vaccines were cited as growth catalysts.
Comentarios